Can targeted metabolomics predict depression recovery? Results from the CO-MED trial

Metabolomics is a developing and promising tool for exploring molecular pathways underlying symptoms of depression and predicting depression recovery. The AbsoluteIDQ™ p180 kit was used to investigate whether plasma metabolites (sphingomyelins, lysophosphatidylcholines, phosphatidylcholines, and acy...

Descripción completa

Detalles Bibliográficos
Autores principales: Czysz, Andrew H., South, Charles, Gadad, Bharathi S., Arning, Erland, Soyombo, Abigail, Bottiglieri, Teodoro, Trivedi, Madhukar H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341111/
https://www.ncbi.nlm.nih.gov/pubmed/30664617
http://dx.doi.org/10.1038/s41398-018-0349-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341111/
https://www.ncbi.nlm.nih.gov/pubmed/30664617
http://dx.doi.org/10.1038/s41398-018-0349-6

Ejemplares similares